BioTime Inc (NYSE American:BTX)

2.36
BATS BZX Real-Time Price
As of 9:58am ET
 -0.04 / -1.67%
Today’s Change
1.98
Today|||52-Week Range
3.16
+9.77%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$277.9M

Company Description

BioTime, Inc. is a clinical-stage biotechnology company, which deals with degenerative diseases. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

Contact Information

BioTime, Inc.
1010 Atlantic Avenue
Alameda California 94501-7850
P:(510) 521-3390
Investor Relations:

Employees

Shareholders

Other institutional38.24%
Individual stakeholders35.46%
Mutual fund holders13.23%

Top Executives

Michael D. WestCo-Chief Executive Officer & Director
Adi MohantyPresident, Co-Chief Executive Officer & Director
Russell L. SkibstedChief Financial & Accounting Officer
Gary S. HoggeSenior Vice President-Clinical & Medical Affairs
Stephana E. PattonSecretary, Compliance Officer & General Counsel